SLC6A3 and Parkinson disease: Such small molecules could potentially be useful for the treatment of Dopamine Transporter Deficiency Syndrome (DTDS), a rare genetic form of infantile parkinsonism associated with the misfolding of SLC6A3 dopamine transporter variants (95).